


Athletes and public could benefit from new research on reduction of upper respiratory tract illness

June 14 2024, by Gary Hughes



Credit: Pixabay/CC0 Public Domain

The preliminary findings from the latest research into the benefits of a commercially available throat spray for endurance athletes has shown that it may shorten the duration of upper respiratory tract illnesses (URTI) such as coughs and colds by up to five days.

This research on the effects of ColdZyme, which is being conducted by Professor Glen Davison at the School of Sport and Exercise Sciences, will not only have obvious benefits for athletes who are required to train and perform during cold and flu "season" but also the general population for whom symptoms can affect general health as well as impact on well-being and work productivity.

Professor Davison has been conducting research on ColdZyme since 2017.

For his latest study, the preliminary findings of which he presented to the International Olympic Committee (IOC) [world conference](#) on Prevention of Injury and Illness in Sport earlier this year, approximately 160 [endurance athletes](#) were monitored over the winter months in the UK. They were randomized to placebo or ColdZyme and required to monitor their training, and illness symptoms daily.

If they suspected a cold (or other URTI), they were required to take a self-swab from their throat on days 1, 3, 5, and 7 of perceived URTI, which were later analyzed for the presence of viruses or bacteria that might be causing the infection.

Initial observations have shown that symptoms are milder, and illness duration is shorter. The swab analysis also shows lower viral load (for Rhinovirus, the most common URTI causing pathogen) with ColdZyme. Results for other pathogens will be presented in the full study.

Professor Davison also discussed his latest research when part of a panel on Innovations in Global Health Technologies in Geneva on 31 May.

He said, "This study has now finished, and we are in the process of completing all final analysis, hoping to publish the full results in peer-reviewed scientific outputs later this year. The findings are really

exciting, and the reduction in [illness](#) duration could be of real practical benefit to athletes, and the wider population."

This [research](#) was funded by Enzymatica, maker of the ColdZyme product.

Provided by University of Kent

Citation: Athletes and public could benefit from new research on reduction of upper respiratory tract illness (2024, June 14) retrieved 11 July 2024 from <https://medicalxpress.com/news/2024-06-athletes-benefit-reduction-upper-respiratory.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.